Uniquely formulated to address specific dermal infections, the NanoStat™ technology has demonstrated remarkable clinical efficacy and safety in over 1000 patients in three indications, herpes labialis, acne and onychomycosis. In addition, preclinical studies have demonstrated activity against numerous other bacterial, viral and fungal pathogens.